17
Registered trials
2
Recruiting
7
Unique sponsors
8
Unique IMPs
17
Commercial trials
Drug classes (ATC)
—
ATC code not specified
12
N
Neurology/Psychiatry (ATC N)
3
J
Anti-infectives (ATC J)
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
5 substances
Antiviral
2 substances
Vaccine
1 substance
Phase III:
4
Phase II/III:
1
Phase II:
4
Phase I:
3
Phase I (Other):
5
Phase III
4 trials-
EndedGlaxoSmithKline Biologicals CommercialPNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14 CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO CRM197 ADSORBED ON ALUMINIUM PHOSPHATE; RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION F PROTEIN, ADJUVANTED WITH AS01E
-
EndedGlaxoSmithKline Biologicals CommercialRESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E
-
EndedGlaxoSmithKline Biologicals CommercialRESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E
-
EndedSanofi Pasteur Commercial534
Phase II/III
1 trial-
EndedMerck Sharp & Dohme LLC CommercialIMP not specified
Phase II
4 trials-
PendingBiothervax SpA CommercialMYCOBACTERIUM BOVIS BACILLUS CALMETTE-GUÉRIN, STRAIN DANISH 1331, LIVE, EXPRESSING RESPIRATORY SYNCYTIAL VIRUS, NUCLEOPROTEIN
-
EndedEnanta Pharmaceuticals Inc. CommercialZELICAPAVIR
-
RecruitingGlaxoSmithKline Biologicals CommercialRESPIRATORY SYNCYTIAL VIRUS, GLYCOPROTEIN F, RECOMBINANT, STABILISED IN THE PRE-FUSION CONFORMATION, ADJUVANTED WITH AS01E
-
RecruitingShionogi B.V. CommercialIMP not specified
Phase I
3 trials-
EndedGlaxoSmithKline Biologicals CommercialIMP not specified
-
EndedMerck Sharp & Dohme LLC CommercialIMP not specified
-
EndedPfizer Inc. CommercialIMP not specified
Phase I (Other)
5 trials-
EndedMerck Sharp & Dohme LLC CommercialIMP not specified
-
EndedMerck Sharp & Dohme LLC CommercialIMP not specified
-
Not authorisedPfizer Inc. CommercialSISUNATOVIR
-
EndedPfizer Inc. CommercialDENATONIUM BENZOATE; SISUNATOVIR
-
EndedPfizer Inc. CommercialIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| GlaxoSmithKline Biologicals | Commercial | 5 | Phase I, Phase II, Phase III | 1 |
| Merck Sharp & Dohme LLC | Commercial | 4 | Phase I, Phase II/III, Phase I (Other) | 0 |
| Pfizer Inc. | Commercial | 4 | Phase I, Phase I (Other) | 0 |
| Biothervax SpA | Commercial | 1 | Phase II | 0 |
| Enanta Pharmaceuticals Inc. | Commercial | 1 | Phase II | 0 |
| Shionogi B.V. | Commercial | 1 | Phase II | 1 |
| Sanofi Pasteur | Commercial | 1 | Phase III | 0 |
New trials by year
2022
1
2023
6
2024
6
2025
1
2026
1